Company / SG&A Expense
Apellis Pharmaceuticals, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$550.3M
FY2025
5-year range
$176.8M / $550.3M
FY2021-FY2025
Trend
+9.8%
vs FY2024
Sector context
#33 of 213
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s sg&a expense of $550M is higher than 85% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $4M in FY2016 to $550M in FY2025.
Based on SEC 10-K filings.
$550M in FY2025 with a 5-year CAGR of +31.6%. Top quartile in the Health Care sector.
Increased from $501M to $550M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +25.7%
- 5-Year CAGR
- +31.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 213This company $550.3M Sector average $722.3M
▼
-23.8% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +31.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 9.8% year-over-year.
- Ranks #33 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $550.3M | +9.8% |
| FY2024 | $501.1M | +0.0% |
| FY2023 | $500.8M | +80.7% |
| FY2022 | $277.2M | +56.8% |
| FY2021 | $176.8M | +26.8% |
| FY2020 | $139.4M | +107.9% |
| FY2019 | $67.0M | +196.2% |
| FY2018 | $22.6M | +116.4% |
| FY2017 | $10.5M | +143.1% |
| FY2016 | $4.3M | -32.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026